BSE · 523144 · Realty
Medi-Caps Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹1 Cr with net profit ₹-0 Cr — a -58.49% net margin, versus 37.66% the period before.
Shareholding
As of 2026-06-30
- Promoter51.44%
- Public48.54%
- DII0.02%
10,209 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.24× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Construction · ranked #233 of 365 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| DLF Limited | ₹1,62,096 Cr | 127.9 | 3.56 | 9.71% | 0.54% |
| Lodha Developers Limited | ₹1,28,603 Cr | 31.17 | 5.63 | 14.72% | 22.69% |
| Prestige Estates Projects Ltd. | ₹68,693 Cr | 57.45 | 4.22 | 7.35% | 9.42% |
| The Phoenix Mills Ltd. | ₹67,523 Cr | 51.87 | 6.14 | 11.14% | 28.16% |
| Oberoi Realty Limited | ₹65,972 Cr | 24.92 | 3.68 | 13.99% | 41.59% |
| Godrej Properties Ltd. | ₹63,586 Cr | 97.82 | 3.32 | 9.66% | 0.36% |
| Knowledge Realty Trust | ₹52,867 Cr | 84.55 | 1.21 | 0.87% | 14.62% |
| Rail Vikas Nigam Limited | ₹46,471 Cr | 53.07 | 4.73 | 8.91% | 4.29% |
| Embassy Office Parks REIT | ₹40,674 Cr | 147.97 | 1.98 | 1.37% | 7.39% |
| Bagmane Prime Office REIT | ₹35,629 Cr | 39.79 | — | 0% | 0% |
| Medi-Caps Ltd.(this company) | ₹33 Cr | 10.72 | 0.29 | -2.72% | -24.52% |
AI analysis
AI-generated · google/gemini-2.5-flashMedi-Caps Ltd., operating in the Realty sector, has a market capitalization of Rs 32 Cr. The company's PE ratio is 10.76 and its book value stands at Rs 89.5. It reported a profit margin of -24.52%.
Positives
- +The debt-to-equity ratio is 0, indicating no debt.
- +Promoter holding of 51.4425% is above 50% as of June 30, 2026.
- +There are no shares pledged by the promoters, with promoter pledge at 0%.
Negatives
- −The Return on Equity (ROE) is -272.15%, indicating significant losses.
- −The Return on Capital Employed (ROCE) is -2.6972%, reflecting inefficient capital utilization.
- −The company reported a negative profit margin of -24.52%.
- −Earnings per share (EPS) for March 2025 was -0.46, indicating a loss per share.
- −Promoter holding decreased from 50.136% in March 2018 to 2016 to 51.4425% in June 2026.
Financial Performance
In the annual period ending March 2025, Medi-Caps Ltd. reported a revenue of Rs 28.2066 Cr, with a net loss of Rs 0.571 Cr. For the quarter ending March 2026, the company recorded a revenue of Rs 3.45 Cr and a net profit of Rs 3.04 Cr. However, the preceding quarter ending December 2025 showed a revenue of Rs 4.3 Cr and a net loss of Rs 0.77 Cr.
Profitability & Returns
Medi-Caps Ltd. reported a negative Return on Equity (ROE) of -272.15% and a negative Return on Capital Employed (ROCE) of -2.6972%. The annual earnings per share (EPS) for March 2025 was -0.46. The company’s profit margin is -24.52%.
Balance Sheet
The company maintains a debt-to-equity ratio of 0, indicating no debt. The book value per share is Rs 89.5. No information on revenue or profit growth is disclosed in the provided data.
Ownership & Pledges
As of June 30, 2026, the promoter holding in Medi-Caps Ltd. was 51.4425%, with the public holding 48.5358%. Domestic institutional investors (DII) held 0.0217% of the shares. There are no pledged shares by the promoters.
Regulatory & Surveillance
The company is not currently under any surveillance measure. There were no FII holdings reported as of June 30, 2026.
Data as of — price: 2026-07-31 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.